Finance Watch: Intrexon Reorganizes, Raises Cash And Becomes Precigen
Executive Summary
The new year starts with a strategic shift by Intrexon. Also, Roivant and Sumitomo Dainippon launch Sumitovant, Melinta reorganizes through Chapter 11 bankruptcy, Acorda arranges debt relief and CF PharmTech raises a $90m series E round.
You may also be interested in...
Industry Refuses To Let Congress Forget PASTEUR Act
Melinta CEO and a representative of the Infectious Diseases Society of America call on a Senate HELP subcommittee to push for passage of PASTEUR Act. Introduced in the Senate and House for the third time this year, the measure would establish a subscription model to pay drug developers upfront for certain antimicrobials.
US FDA Rejects Melinta Effort To Go Beyond Court Order In FedEx-Driven ANDA Dispute
Court found FDA erred in finding Melinta received notice of Paragraph IV certification for generic Minocin on date specified by Nexus. Agency will not require Nexus to send a new notice or give Melinta heads up of final approval of the ANDA.
Finance Watch: Argenx Raises $1.15bn For Efgartigimod Commercialization
Public Company Edition: Among other recent large financings, BridgeBio Pharma launched a $650m note sale, CureVac closed a $517.5m follow-on offering and Revolution Medicines raised $260.9m.